Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

vertex pharmaceuticals inc. - VRTX

VRTX

Close Chg Chg %
432.17 1.44 0.33%

Closed Market

433.61

+1.44 (0.33%)

Volume: 727.91K

Last Updated:

Nov 28, 2025, 1:00 PM EDT

Trade Now

Company Overview: vertex pharmaceuticals inc. - VRTX

VRTX Key Data

Open

$434.67

 Day Range

429.07 - 434.67

52 Week Range

362.50 - 519.68

 Market Cap

$109.65B

Shares Outstanding

253.72M

 Public Float

253.05M

Beta

0.36

 Rev. Per Employee

N/A

P/E Ratio

30.46

 EPS

$14.32

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.45M

  

VRTX Performance

1 Week
 
 1.61%
 
1 Month
 
 1.89%
 
3 Months
 
 10.89%
 
1 Year
 
 -7.37%
 
5 Years
 
 91.26%
 

VRTX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 36
Full Ratings ➔

About vertex pharmaceuticals inc. - VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

VRTX At a Glance

Vertex Pharmaceuticals, Inc.
50 Northern Avenue
Boston, Massachusetts 02210
Phone 1-617-341-6100 Revenue 10.98B
Industry Pharmaceuticals: Major Net Income -535,600,000.00
Sector Health Technology 2024 Sales Growth 11.641%
Fiscal Year-end 12 / 2025 Employees 6,100
View SEC Filings

VRTX Valuation

P/E Current 30.459
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 9.455
Price to Book Ratio 6.305
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 21.793
Enterprise Value to Sales 9.057
Total Debt to Enterprise Value 0.018

VRTX Efficiency

Revenue/Employee 1,800,721.311
Income Per Employee -87,803.279
Receivables Turnover 6.825
Total Asset Turnover 0.476

VRTX Liquidity

Current Ratio 2.692
Quick Ratio 2.354
Cash Ratio 1.716

VRTX Profitability

Gross Margin 86.067
Operating Margin 39.686
Pretax Margin 2.262
Net Margin -4.876
Return on Assets -2.32
Return on Equity -3.152
Return on Total Capital -2.949
Return on Invested Capital -2.945

VRTX Capital Structure

Total Debt to Total Equity 10.661
Total Debt to Total Capital 9.634
Total Debt to Total Assets 7.577
Long-Term Debt to Equity 10.099
Long-Term Debt to Total Capital 9.126
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Vertex Pharmaceuticals Inc. - VRTX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
7.60B 8.75B 9.84B 10.98B
Sales Growth
+22.47% +15.04% +12.47% +11.64%
Cost of Goods Sold (COGS) incl D&A
904.20M 1.08B 1.26B 1.53B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
125.60M 148.30M 181.30M 205.80M
Depreciation
125.60M 148.30M 167.80M 160.40M
Amortization of Intangibles
- - 1.70M 20.20M
-
COGS Growth
+22.80% +19.48% +16.84% +21.26%
Gross Income
6.70B 7.67B 8.58B 9.45B
Gross Income Growth
+22.42% +14.44% +11.85% +10.23%
Gross Profit Margin
+88.11% +87.65% +87.17% +86.07%
2021 2022 2023 2024 5-year trend
SG&A Expense
3.89B 3.48B 4.30B 5.09B
Research & Development
3.05B 2.54B 3.16B 3.63B
Other SG&A
840.10M 944.70M 1.14B 1.46B
SGA Growth
+49.66% -10.44% +23.37% +18.49%
Other Operating Expense
- - - -
-
Unusual Expense
(1.60M) 230.00M 478.60M 4.63B
EBIT after Unusual Expense
2.81B 3.95B 3.80B (266.40M)
Non Operating Income/Expense
(18.70M) 321.30M 625.20M 545.50M
Non-Operating Interest Income
4.90M 144.60M 614.70M 598.10M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
61.50M 54.80M 44.10M 30.60M
Interest Expense Growth
+5.76% -10.89% -19.53% -30.61%
Gross Interest Expense
61.50M 54.80M 44.10M 30.60M
Interest Capitalized
- - - -
-
Pretax Income
2.73B 4.23B 4.38B 248.50M
Pretax Income Growth
-12.40% +55.01% +3.48% -94.33%
Pretax Margin
+35.91% +48.38% +44.51% +2.26%
Income Tax
388.30M 910.40M 760.20M 784.10M
Income Tax - Current - Domestic
401.40M 813.90M 946.60M 823.10M
Income Tax - Current - Foreign
141.50M 372.40M 350.10M 309.80M
Income Tax - Deferred - Domestic
(56.20M) (415.00M) (591.80M) (487.40M)
Income Tax - Deferred - Foreign
(98.40M) 139.10M 55.30M 138.60M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
2.34B 3.32B 3.62B (535.60M)
Minority Interest Expense
- - - -
-
Net Income
2.34B 3.32B 3.62B (535.60M)
Net Income Growth
-13.63% +41.84% +8.96% -114.80%
Net Margin Growth
+30.80% +37.97% +36.79% -4.88%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
2.34B 3.32B 3.62B (535.60M)
Preferred Dividends
- - - -
-
Net Income Available to Common
2.34B 3.32B 3.62B (535.60M)
EPS (Basic)
9.0885 12.9715 14.0458 -2.0768
EPS (Basic) Growth
-12.91% +42.72% +8.28% -114.79%
Basic Shares Outstanding
257.70M 256.10M 257.70M 257.90M
EPS (Diluted)
9.0115 12.8213 13.8948 -2.0768
EPS (Diluted) Growth
-12.47% +42.28% +8.37% -114.95%
Diluted Shares Outstanding
259.90M 259.10M 260.50M 257.90M
EBITDA
2.93B 4.33B 4.46B 4.57B
EBITDA Growth
-1.61% +47.59% +2.94% +2.39%
EBITDA Margin
+38.59% +49.51% +45.32% +41.56%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 487.20
Number of Ratings 36 Current Quarters Estimate 5.122
FY Report Date 12 / 2025 Current Year's Estimate 18.491
Last Quarter’s Earnings 4.80 Median PE on CY Estimate N/A
Year Ago Earnings 0.42 Next Fiscal Year Estimate 20.286
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 25 9 25 28
Mean Estimate 5.12 4.79 18.49 20.29
High Estimates 5.78 5.48 19.15 24.95
Low Estimate 4.46 4.03 17.75 17.71
Coefficient of Variance 6.10 10.00 2.02 8.36

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 19 20 19
OVERWEIGHT 2 1 1
HOLD 13 12 13
UNDERWEIGHT 2 2 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Vertex Pharmaceuticals Inc. - VRTX

Date Name Shares Transaction Value
Nov 21, 2025 Lloyd A. Carney Director 6,315 Bona fide gift 0.00
Jul 18, 2025 Bruce I. Sachs Director 15,342 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 18, 2025 Suketu P. Upadhyay Director 2,552 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 David Matthew Altshuler EVP, Chief Scientific Officer 23,281 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $424.69 per share 9,887,207.89
Mar 7, 2025 Ourania Tatsis EVP, Chief Reg. & Quality Off. 54,481 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $485.49 per share 26,449,980.69
Mar 3, 2025 Stuart A. Arbuckle EVP, COO 62,935 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share 30,184,255.35
Mar 3, 2025 Ourania Tatsis EVP, Chief Reg. & Quality Off. 58,539 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $475.34 per share 27,825,928.26
Mar 3, 2025 Reshma Kewalramani CEO & President; Director 105,915 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share 50,797,893.15
Mar 3, 2025 Kristin Ambrose SVP & Chief Accounting Officer 7,845 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share 3,762,540.45
Mar 3, 2025 Carmen Bozic EVP and CMO 32,669 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share 15,668,379.09
Mar 3, 2025 Edward Morrow Atkinson EVP, Chief Technical Ops. Off. 22,002 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share 10,552,379.22
Mar 3, 2025 Charles F. Wagner EVP & Chief Financial Officer 54,969 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share 26,363,682.09
Mar 3, 2025 Edward Morrow Atkinson EVP, Chief Technical Ops. Off. 19,352 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $475.34 per share 9,198,779.68
Mar 3, 2025 Amit K. Sachdev EVP Chief Patient & Ext Af Off 68,490 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $479.61 per share 32,848,488.90
Mar 3, 2025 David Matthew Altshuler EVP, Chief Scientific Officer 32,974 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $480 per share 15,827,520.00
Feb 27, 2025 Kristin Ambrose SVP & Chief Accounting Officer 9,086 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $480.95 per share 4,369,911.70
Feb 20, 2025 Jeffrey M. Leiden Executive Chairman; Director 24,026 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $463.46 per share 11,135,089.96
Feb 20, 2025 Jonathan Prim Biller EVP and Chief Legal Officer 19,263 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $463.46 per share 8,927,629.98
Feb 20, 2025 Jonathan Prim Biller EVP and Chief Legal Officer 17,606 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $455.06 per share 8,011,786.36
Feb 20, 2025 Nia Tatsis EVP, Chief Reg. & Quality Off. 67,939 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $463.46 per share 31,487,008.94

Vertex Pharmaceuticals Inc. in the News